Medical technology sits at the center of this dementia and brain health question.

Catalyst MedTech announced on March 25, 2026 that it is establishing the full national deployment of its Full Access Neurology solution as the industry standard for Brain PET implementation in the U.S., positioning the company as the definitive partner for Alzheimer’s disease diagnosis through advanced imaging. This development marks a significant consolidation in how medical institutions across the country will access and operate brain imaging technology, directly addressing the fragmented landscape of nuclear medicine services that have previously complicated early Alzheimer’s diagnosis. For a patient experiencing early memory concerns, this standardized approach means more consistent access to high-resolution brain PET imaging that can detect the telltale amyloid and tau deposits characteristic of Alzheimer’s disease—often before symptoms become severe enough to impair daily functioning.

The Full Access Neurology standard encompasses far more than Alzheimer’s alone. Catalyst MedTech has secured exclusive U.S. distribution of the ultra-high-resolution CareMiBrain™ technology for brain imaging, paired with comprehensive OEM-level service capabilities and one of the largest multi-vendor support networks in nuclear medicine. This article examines what this industry standard means for patients, clinicians, and the evolving landscape of brain health diagnosis, explores the clinical evidence driving these imaging standards, and explains why consistent access to advanced brain imaging has become essential in the era of disease-modifying Alzheimer’s treatments.

Why Brain Imaging Standards Matter for Alzheimer’s Diagnosis
The Full Access Neurology Solution and CareMiBrain™ Technology
How Advanced Imaging Addresses Multiple Brain Conditions
Updated Clinical Guidelines Driving Standardized Implementation
Blood-Based Biomarkers and the Continuing Evolution of Diagnostic Standards
Advanced Imaging Breakthroughs: Detecting Alzheimer’s Years Before Symptoms
Standardization and the Future of Equitable Dementia Care
Conclusion

Why Brain Imaging Standards Matter for Alzheimer’s Diagnosis

Alzheimer’s disease begins silently in the brain, with pathological changes—primarily the accumulation of amyloid-beta and tau proteins—developing years before a person notices memory problems. Brain pet imaging can visualize these molecular hallmarks directly, making it one of the most specific tools available for early detection and diagnosis. Without standardized access to this technology, diagnostic accuracy varies dramatically between medical centers, and patients in underserved regions may face months-long wait times or travel significant distances for imaging. The clinical relevance of this standardization cannot be overstated, particularly given recent advances in disease-modifying treatments. Lecanemab and other anti-amyloid monoclonal antibodies have shown promise in slowing cognitive decline in early Alzheimer’s disease, but they work best when administered early—before significant neurodegeneration occurs.

Without reliable access to amyloid and tau PET imaging, patients miss the diagnostic window when these treatments are most effective. Catalyst MedTech’s standardized Full Access Neurology solution addresses this bottleneck by ensuring that institutions nationwide can offer consistent, timely brain imaging assessments. However, standardization around one technology platform also carries a limitation worth noting: institutional flexibility becomes constrained. Medical centers that have invested in different PET imaging systems may face difficult upgrade decisions, potentially disrupting existing workflows or requiring substantial capital expenditure. The standard’s strength—consistency and comprehensive service support—also creates a degree of vendor consolidation that clinic administrators must carefully evaluate.

Why Brain Imaging Standards Matter for Alzheimer's Diagnosis

The Full Access Neurology Solution and CareMiBrain™ Technology

Catalyst MedTech’s Full Access Neurology solution centers on the CareMibrain™ imaging system, an ultra-high-resolution brain PET scanner designed specifically to capture detailed images of the structures and neurochemistry most relevant to neurodegenerative disease. The CareMiBrain™ technology provides superior spatial resolution compared to conventional whole-body PET systems, allowing clinicians to detect subtle regional patterns of amyloid and tau accumulation that might be missed on lower-resolution imaging. This granular diagnostic capability is particularly valuable for differentiating Alzheimer’s disease from other neurodegenerative conditions that present with similar symptoms. The comprehensive service ecosystem surrounding CareMiBrain™ includes OEM-level maintenance support and one of the largest multi-vendor support networks in nuclear medicine. This is a critical operational advantage for medical centers, as PET imaging systems are complex instruments requiring specialized technician expertise and rapid response to technical issues.

By centralizing service through Catalyst MedTech, institutions reduce downtime and improve the reliability of their imaging programs—meaning more consistent availability of brain imaging slots for patients. This is especially important in a healthcare environment where imaging backlogs directly translate to delayed diagnosis and treatment initiation. One practical consideration: the CareMiBrain™ standard represents a significant capital investment for institutions not yet equipped with dedicated brain PET capability. While the full-service support model may reduce long-term operational costs, clinics and hospitals must weigh this investment against the demonstrated clinical benefit of standardized, accessible brain imaging. The economic case is strongest for high-volume imaging centers in metropolitan areas, where patient demand justifies the equipment investment.

How Advanced Imaging Addresses Multiple Brain Conditions

While Alzheimer’s disease dominates headlines in dementia care, the standardized brain PET platform through Catalyst MedTech also addresses imaging needs across a broader spectrum of neurological conditions. The Full Access Neurology solution has been positioned to serve patients with Lewy body dementia, frontotemporal dementia, brain tumors, chronic traumatic encephalopathy (CTE), and psychiatric disorders. Each of these conditions has distinct neurochemical signatures—different patterns of protein accumulation, dopamine depletion, or metabolic dysfunction—that specialized brain imaging can reveal. For example, a patient with progressive cognitive decline and hallucinations might have Lewy body dementia rather than Alzheimer’s disease; the two conditions respond differently to medication, and accurate differentiation through imaging directly influences treatment decisions.

Similarly, athletes and military veterans concerned about CTE can benefit from amyloid and tau PET imaging to assess whether repetitive head trauma has initiated the neuropathological cascade characteristic of CTE. By establishing a single standardized platform capable of detecting multiple conditions, Catalyst MedTech has simplified the technical and operational complexity that previously fragmented brain imaging across competing systems and protocols. The scope of conditions covered also highlights an important limitation: not all neuropsychiatric presentations benefit equally from PET imaging. Depression, anxiety, or primary psychiatric disorders without structural or molecular pathology may not show clear abnormalities on amyloid/tau PET. In these cases, standardized imaging access doesn’t reduce clinical uncertainty, and clinicians must continue to rely on history, neuropsychological testing, and MRI to guide diagnosis and treatment.

How Advanced Imaging Addresses Multiple Brain Conditions

Updated Clinical Guidelines Driving Standardized Implementation

The timing of Catalyst MedTech’s industry standard announcement aligns with significant shifts in clinical practice guidelines. In January 2025, the Alzheimer’s Association and the Society for Nuclear Medicine and Molecular Imaging (SNMMI) released updated Appropriate Use Criteria (AUC) for amyloid and tau PET imaging. These guidelines were driven by the emergence of disease-modifying treatments that require documented amyloid pathology for patient eligibility—a fundamentally different clinical scenario than the previous era, when PET imaging was primarily used for confirmation and prognosis after diagnosis was already clinically apparent. The updated guidelines expand appropriate use cases for brain PET imaging, meaning more patients now have evidence-based justification for accessing these scans. This increased clinical demand directly motivated the establishment of standardized implementation standards like Catalyst MedTech’s Full Access Neurology solution.

When guidelines expand indications, the diagnostic infrastructure must simultaneously expand; otherwise, imaging capacity becomes a bottleneck that prevents guideline-concordant care. Standardization ensures that as patient demand grows, the imaging pipeline can reliably scale across institutions without the variability that has historically characterized nuclear medicine programs. However, expanded guidelines have also created new complexity: not all patients meeting guideline criteria need identical imaging protocols or follow-up intervals. Some patients benefit from serial imaging to track pathological progression over time, while others need a single baseline scan for treatment eligibility assessment. The standardized platform must remain flexible enough to accommodate these clinical variations while maintaining the operational consistency that standardization is designed to provide.

Blood-Based Biomarkers and the Continuing Evolution of Diagnostic Standards

Concurrent with advances in imaging standards, blood-based biomarkers have emerged as a potentially more accessible alternative to PET imaging and cerebrospinal fluid (CSF) testing. In July 2025, the Alzheimer’s Association released clinical practice guidelines at the Alzheimer’s Association International Conference (AAIC) permitting blood-based biomarker tests with at least 90% sensitivity and 90% specificity to substitute for PET imaging or CSF testing in certain diagnostic scenarios. This guideline change suggests that the diagnostic landscape for Alzheimer’s may be shifting toward a mixed model where standardized brain imaging and advanced blood biomarkers coexist rather than one replacing the other. The potential advantage of blood-based biomarkers is accessibility and cost: a simple blood draw performed in any outpatient clinic is far more feasible for widespread screening than a specialized PET scan at a limited number of imaging centers. However, many commercial blood biomarker tests currently available do not yet meet the Alzheimer’s Association’s 90% sensitivity and 90% specificity thresholds.

This performance gap means that while blood biomarkers are increasingly useful for risk stratification and patient selection, they do not yet universally substitute for imaging confirmation in clinical practice. Catalyst MedTech’s standardized imaging platform actually benefits from this coexistence: blood biomarkers can identify at-risk patients who then proceed to confirmatory brain PET imaging through the standardized Full Access Neurology network. The critical limitation to understand is that biomarker adequacy is defined by rigorous performance standards—90% sensitivity and specificity is a high bar. A blood test that correctly identifies amyloid pathology in 85% of cases is clinically useful for some purposes but falls short of the guideline standard for substituting for imaging. As additional blood biomarker assays undergo clinical validation, some will likely cross this threshold while others remain niche applications. The standardized imaging platform serves as the gold standard reference against which these emerging biomarkers are being validated.

Blood-Based Biomarkers and the Continuing Evolution of Diagnostic Standards

Advanced Imaging Breakthroughs: Detecting Alzheimer’s Years Before Symptoms

Beyond conventional amyloid and tau PET imaging, recent breakthroughs have demonstrated that other advanced imaging modalities can detect neurobiological changes even earlier in the Alzheimer’s disease continuum. In September 2025, the Kennedy Krieger Institute published research showing that quantitative susceptibility mapping (QSM) MRI—a specialized form of magnetic resonance imaging that detects changes in tissue iron and other minerals—can identify brain changes years before memory problems begin. This advancement enables earlier risk identification and facilitates enrollment of presymptomatic individuals into clinical trials testing preventive interventions. QSM MRI’s ability to detect pathology decades in advance of symptom onset could fundamentally reshape the timeline of Alzheimer’s diagnosis and intervention.

Rather than waiting for cognitive decline to become noticeable, individuals at genetic risk (carrying the APOE4 allele, for example) or with family histories of dementia could be identified and enrolled in preventive treatment trials during the asymptomatic stage. This represents a paradigm shift from treatment-of-disease toward prevention-of-disease—a far more ambitious goal that depends on earlier and earlier detection. However, QSM MRI is not yet widely available, and its clinical application in routine practice remains experimental. Catalyst MedTech’s standardized brain imaging platform focuses on the more immediately clinically applicable amyloid and tau PET imaging, but the field’s trajectory suggests that future standards may need to incorporate additional modalities as their clinical utility becomes established.

Standardization and the Future of Equitable Dementia Care

The establishment of an industry standard for brain PET implementation represents not merely a technical consolidation but a statement about democratizing access to advanced neuroimaging. Historically, patients in rural areas, smaller cities, and underserved communities have faced significant barriers to obtaining specialized brain imaging—sometimes traveling hundreds of miles or experiencing months-long delays. Standardized implementation through a unified service and support network has the potential to reduce these disparities, though much depends on how widely Catalyst MedTech distributes the CareMiBrain™ system across diverse geographic and institutional settings.

Looking forward, the field of Alzheimer’s diagnosis will likely move toward an integrated model where standardized structural and molecular imaging (PET), emerging advanced MRI techniques like QSM, and validated blood biomarkers all play complementary roles. No single diagnostic modality will be sufficient for all clinical scenarios; instead, clinicians will select among options based on urgency, patient factors, and availability. Catalyst MedTech’s standardized platform positions itself as the infrastructure backbone for imaging in this more complex future, but continued innovation in competing modalities and biomarkers will likely reshape the landscape further in the coming years.

Conclusion

Catalyst MedTech’s establishment of the Full Access Neurology solution as the industry standard for Brain PET implementation represents a significant consolidation of neuroimaging infrastructure in the United States. By standardizing around the ultra-high-resolution CareMiBrain™ technology and comprehensive service support, the company has addressed a longstanding fragmentation in brain imaging access that previously created diagnostic delays and geographic inequities. For patients with Alzheimer’s disease, Lewy body dementia, and other neurodegenerative conditions, standardized access to timely, high-quality brain imaging is increasingly essential—particularly now that disease-modifying treatments require confirmed pathology for patient selection.

The next step for patients, clinicians, and care systems is to understand what standardized brain imaging availability means for their specific circumstances. If you or a loved one is experiencing cognitive concerns, discuss with your primary care physician whether brain PET imaging through the standardized Catalyst MedTech network is appropriate. For healthcare institutions, now is the time to evaluate capital investment in the CareMiBrain™ platform against projected patient demand and the growing clinical evidence supporting early neuroimaging. The diagnostic landscape for Alzheimer’s disease is evolving rapidly, but one principle remains constant: earlier, more accessible, and more accurate diagnosis creates more opportunities for effective intervention.